Also trades as: SNBIF (OTC) · $vol 0M
4592.T JPX
SanBio Company Limited
1W: -16.6%
1M: -24.8%
3M: -25.7%
YTD: -22.9%
1Y: -7.8%
3Y: +121.0%
5Y: -12.1%
¥1,530.00 ($9.61)
+12.00 (+0.79%)
Weekly Expected Move ±10.6%
¥1427
¥1619
¥1811
¥2003
¥2195
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap¥119.4B ($750.2M)
52W Range1387-3990
Volume1,587,200
Avg Volume1,404,168
Beta0.31
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOKeita Mori
Employees29
SectorHealthcare
IndustryBiotechnology
IPO Date2015-04-08
Websitesanbio.jp
St. Luke Tower
Tokyo 104-0044
JP
Tokyo 104-0044
JP
81 3 6264 3481
About SanBio Company Limited
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
Latest News
No recent news
Recent Insider Trades
No insider trades found